Refining the role of PARP inhibitors in targeted anticancer therapy

Developments in immunotherapy

Using Hsp90 inhibitors in the clinic: what have we learned?

Radiogenomic evaluation of tumour response to targeted agents

Drugging the cancer genome to overcome drug resistance

High BMI beneficial in kidney cancer

Optimizing survival in advanced prostate cancer: Welcome and introduction

Epigenome deregulation in cancer

Cancer control through vaccination requires global collaboration

Cancer and the immune system: exploring the landscape of cancer immunology

Inspiring movement towards a global vision of cancer control

Comment: Impact of combined bevacizumab and presurgery chemo varies by subtype